Changeflow GovPing

What do you monitor?

Curated feeds for your role. Pick your area and get exactly the sources you need.

Recent changes

1mo ago FTC Press Releases
Favicon for www.ftc.gov

FTC Settlement with Express Scripts to Lower Drug Costs

The FTC has secured a settlement with Express Scripts, Inc. (ESI), a major pharmacy benefit manager, requiring significant changes to its business practices. These changes are projected to lower drug costs for patients by up to $7 billion over 10 years and increase revenue for community pharmacies.

Urgent Enforcement Healthcare
1mo ago FTC Press Releases
Favicon for www.ftc.gov

FTC ANPRM on Rental Housing Fees Submitted to OMB

The FTC has submitted a draft Advance Notice of Proposed Rulemaking (ANPRM) concerning fees in the rental housing market to the Office of Management and Budget (OMB) for review. This action signals the agency's intent to potentially create new rules to address deceptive or unfair fees charged to renters.

Priority review Consultation Consumer Protection
1mo ago FTC Press Releases
Favicon for www.ftc.gov

FTC Draft Rulemaking on Negative Option Plans Submitted for Review

The FTC has submitted a draft Advance Notice of Proposed Rulemaking (ANPRM) concerning its Negative Option Rule to the Office of Management and Budget (OMB) for review. This action indicates the agency is considering potential revisions or new regulations related to negative option plans, which are common in subscription services.

Priority review Consultation Consumer Protection
1mo ago FTC Press Releases
Favicon for www.ftc.gov

FTC Warns 42 Law Firms on Anticompetitive DEI Hiring Practices

The FTC has issued warning letters to 42 law firms regarding potentially anticompetitive employment practices related to Diversity, Equity, and Inclusion (DEI) hiring. The firms, which participated in the Mansfield Certification program, are cautioned that coordinating on candidate pools or sharing pay information may violate antitrust laws.

Priority review Enforcement Antitrust & Competition
Favicon for ico.org.uk

ICO Enforcement Actions

The UK's Information Commissioner's Office (ICO) has published a list of its enforcement actions, including monetary penalties, prosecutions, and reprimands. This page serves as a central repository for these actions across various sectors.

Priority review Enforcement Data Privacy
Favicon for ico.org.uk

ICO FOI Regulatory Actions

The Information Commissioner's Office (ICO) has updated its Freedom of Information (FOI) regulatory actions page. This update includes new notices, recommendations, and practice guidance related to FOI compliance for public authorities in the UK.

Routine Notice Data Privacy
Favicon for ico.org.uk

ICO Recovers Fines and Issues Penalties to DPP Law, 23andMe, Capita

The UK's Information Commissioner's Office (ICO) has recovered fines and issued penalties to several organisations, including DPP Law, 23andMe, and Capita. The ICO details its formal debt recovery actions, which can lead to insolvency proceedings and director disqualifications for non-payment of fines.

Urgent Enforcement Data Privacy
Favicon for www.fda.gov

FDA Guidance on Promotional Labeling for Biosimilar Products

The FDA has issued new guidance addressing promotional labeling and advertising considerations for prescription reference products, biosimilar products, and interchangeable biosimilar products. The guidance aims to ensure promotional communications are accurate, truthful, and non-misleading for manufacturers and their representatives.

Priority review Guidance Pharmaceuticals
Favicon for www.fda.gov

FDA Finalizes Guidance on Drug Dispute Resolution

The FDA has finalized guidance for industry on formal dispute resolution and administrative hearings for drugs subject to final administrative orders under section 505G of the FD&C Act. This guidance provides recommendations for resolving scientific and medical disputes between the Center for Drug Evaluation and Research (CDER) and drug sponsors.

Routine Guidance Pharmaceuticals
Favicon for www.fda.gov

FDA Draft Guidance on Bayesian Methodology in Drug Trials

The FDA has issued draft guidance on the use of Bayesian methodology in clinical trials for drug and biological products. This guidance is intended for sponsors and applicants and focuses on supporting primary inference for effectiveness and safety. The agency is seeking public comments on this draft document.

Priority review Consultation Pharmaceuticals

Showing 14381–14390 of 14,488 changes

1 1437 1438 1439 1440 1441 1449

Get alerts when regulations change

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.